Provided are therapeutic combinations or formulations of drugs comprising triple monoamine reuptake inhibitors, melanin concentrating hormone receptor 1 (MCHRT) antagonists and diazoxide or its formulations and various combinations thereof, these in combination with other drugs or active agents. Provided are methods for the treatment of various conditions, including genetic confirmed syndromes, and diseases, using therapeutic combinations and formulations of drugs as provided herein. Provided are methods for administering triple monoamine reuptake inhibitors (TRIs), melanin concentrating hormone receptor 1 (MCHRT) antagonists and diazoxide or diazoxide or its formulations, whose dosages are determined using a method as provided herein including empirical methods for safe and predictable titration and to determine the initial therapeutic dose; model-based methods for safe and predictable titration and to determine the initial therapeutic dose and to determine the lowest therapeutic dose or to determine an optimal effective dose, including use of Bayesian pharmacometric models.

Melatonin Agonist, MA-1, is administered at effective doses.

Melatonin Agonist, MA-1, is administered at effective doses.

The present invention discloses, in one embodiment, a method of using human induced pluripotent stem cells to generate three-dimensional human organ tissue for therapeutic drug toxicity and discovery⋅. In one embodiment, a high throughput microtiter plate is loaded with both wild type and Rett disease 3D spheroids and exposed to a drug library, and activity is measured and analyzed for disease rescue to wild type cell behavior.

The present invention discloses, in one embodiment, a method of using human induced pluripotent stem cells to generate three-dimensional human organ tissue for therapeutic drug toxicity and discovery⋅. In one embodiment, a high throughput microtiter plate is loaded with both wild type and Rett disease 3D spheroids and exposed to a drug library, and activity is measured and analyzed for disease rescue to wild type cell behavior.

Provided is a use of usnic acid or a salt of usnic acid or a formulation thereof in the preparation of anti-avian coccidiosis drugs or feed additives. Also provided are anti-avian coccidiosis drugs and feed additives comprising usnic acid or a salt of usnic acid or a formulation thereof. Both the use of usnic acid or a salt of usnic acid or a formulation thereof in the preparation of anti-avian coccidiosis drugs or feed additives and anti-avian coccidiosis drugs and feed additives comprising usnic acid or a salt of usnic acid or a formulation thereof provide a new way for treating and preventing avian coccidiosis. The addition of Usnea or usnic acid or a salt of usnic acid or a formulation thereof to feedstuff may realize effective anti-avian coccidiosis.

Provided is a use of usnic acid or a salt of usnic acid or a formulation thereof in the preparation of anti-avian coccidiosis drugs or feed additives. Also provided are anti-avian coccidiosis drugs and feed additives comprising usnic acid or a salt of usnic acid or a formulation thereof. Both the use of usnic acid or a salt of usnic acid or a formulation thereof in the preparation of anti-avian coccidiosis drugs or feed additives and anti-avian coccidiosis drugs and feed additives comprising usnic acid or a salt of usnic acid or a formulation thereof provide a new way for treating and preventing avian coccidiosis. The addition of Usnea or usnic acid or a salt of usnic acid or a formulation thereof to feedstuff may realize effective anti-avian coccidiosis.

A method for preparing a cyclodextrin metal organic framework (CD-MOF) stable in aqueous phase, including: dissolving β-cyclodextrin and solid potassium hydroxide in deionized water followed by magnetic stirring and ultrasonic treatment at room temperature, addition of methanol and stirring to obtain a reaction mixture; filtering the reaction mixture with a polytetrafluoroethylene membrane filter in a beaker; placing the beaker in methanol vapor to form a β-CD-MOF crystal; washing the β-CD-MOF crystal with ethanol followed by centrifugation and vacuum drying to obtain β-CD-MOF; preparing a β-CD-MOF-active substance complex by impregnation; and preparing an active substance-loaded β-CD-MOF-Tween 80 complex by physical adsorption modification followed by washing with anhydrous ethanol and vacuum drying.

A method for preparing a cyclodextrin metal organic framework (CD-MOF) stable in aqueous phase, including: dissolving β-cyclodextrin and solid potassium hydroxide in deionized water followed by magnetic stirring and ultrasonic treatment at room temperature, addition of methanol and stirring to obtain a reaction mixture; filtering the reaction mixture with a polytetrafluoroethylene membrane filter in a beaker; placing the beaker in methanol vapor to form a β-CD-MOF crystal; washing the β-CD-MOF crystal with ethanol followed by centrifugation and vacuum drying to obtain β-CD-MOF; preparing a β-CD-MOF-active substance complex by impregnation; and preparing an active substance-loaded β-CD-MOF-Tween 80 complex by physical adsorption modification followed by washing with anhydrous ethanol and vacuum drying.

There are provided various compositions comprising monoglyceride(s) and cannabinoid(s). These compositions can be useful for increasing the life span of a subject; for increasing the disability-free life expectancy, for slowing down the ageing process of a subject; for increasing the mitochondrial OXPHOS of a subject; for decreasing the mitochondrial LEAK of a subject; for increasing the mitochondrial RCR or COUPLING EFFICIENCY of a subject; and for optimizing the mitochondrial functions of a subject.